Latest news with #Ozempic
Yahoo
an hour ago
- Health
- Yahoo
Weight loss jabs such as Mounjaro linked to lower dementia and stroke risk
Weight loss jabs may offer a protective effect against dementia and stroke, according to a new study. Academics said the benefits of drugs such as Wegovy and Mounjaro – including for managing weight and blood sugar levels – are well known, but other health benefits of the popular drugs remain 'unclear'. People with type 2 diabetes and obesity who are taking the drugs are also less likely to die prematurely, researchers found. The study saw experts from Taiwan examine date on 60,000 people from around the world, with an average age of 58, who had type 2 diabetes and obesity. Key differences between three weight-loss injections: Mounjaro, Wegovy, and Ozempic. — Paul Wischmeyer MD (@Paul_Wischmeyer) July 4, 2025 Around half were given GLP agonist drugs semaglutide and tirzepatide – which are sold under the brand names Wegovy and Mounjaro. Semaglutide is also the main ingredient for the type 2 diabetes drug Ozempic. GLP agonists can reduce a person's appetite; slow down their digestion; reduce the amount of sugar the liver makes and they help the body to make more insulin when needed. The other half used other anti-diabetic medication. 📢Important update Eligible people in #Dorset will be able to access Tirzepatide (Mounjaro) weight management medication from autumn 2025. ✅Around 1,000 people in Dorset will qualify under strict national criteria ✅No need to contact your doctor More: — NHS Dorset (@NHSDorset) June 23, 2025 During a seven-year follow-up period, researchers found that people given the GLP agonist drugs appeared to have a 37% lower risk of dementia and a 19% reduced risk of stroke. They were also 30% less likely to die during the follow-up period. And when researchers looked at the data further they found even greater benefits in people aged 60 or older, women, and those with a body mass index score of 30 to 40. They found no differences in Parkinson's disease or brain bleeds. The academics said their findings suggest 'potential neuroprotective and cerebrovascular benefits' of the drugs but they called for more studies to confirm the findings. Recommended reading: Mounjaro sales adverts banned by watchdog Mounjaro patients report unexpected side-effect Who is eligible for free Mounjaro on the NHS? 'These findings suggest that semaglutide and tirzepatide may offer neuroprotective and cerebrovascular benefits beyond glycemic control, potentially improving long-term cognitive and survival outcomes in adults with type 2 diabetes and obesity,' they wrote in the journal JAMA Network Open. Commenting on the study, Professor Tara Spires-Jones, director of the Centre for Discovery Brain Sciences at the University of Edinburgh and group leader in the UK Dementia Research Institute, said: 'This is a very interesting study adding to evidence that GLP1 receptor agonists are associated with a lower risk of dementia in people with type 2 diabetes and obesity. 'This type of study cannot determine whether the drugs reduced disease risk by directly protecting the brain. 'It is highly likely that effectively treating type 2 diabetes and obesity would reduce dementia and stroke risk as they are known risk factors for these conditions. 'Further work is needed including randomised clinical trials to confirm these drugs are protective in people with diabetes and obesity and other trials are needed to determine whether these drugs will be protective in people who do not have type 2 diabetes and obesity.' Recommended reading: When will Mounjaro be rolled out on the NHS? Travel insurance warning about certain types of policy Warning as Mounjaro and Ozempic sold without prescription Dr Richard Oakley, associate director of research and innovation at Alzheimer's Society, said: 'It is well established that diabetes and obesity can increase your risk of developing dementia. 'This study supports existing evidence that shows these drugs may reduce dementia risk, particularly for people aged 60 and over who are living with type 2 diabetes and obesity. 'Although interesting, we can't draw conclusions from this study alone as it is an observational study, only a small number of people who took part went on to develop dementia and as the impact of these drugs on different types of dementia is not clear. 'There are clinical trials currently looking at whether drugs like these can be used to treat early-stage Alzheimer's disease, so this is a really exciting area being explored in the research fight against dementia.'
NDTV
2 hours ago
- Entertainment
- NDTV
From Kapil Sharma To Bhumi Pednekar: 7 Bollywood Celebrities Who Dropped Serious Weight, And How They Did It
In a country where cinema is a religion and Bollywood stars are idolised as icons, it is no surprise that their every move becomes a talking point. From fashion choices to fitness routines, fans across India closely follow their favourite celebrities not just for entertainment but for lifestyle inspiration. Weight loss, in particular, has become a subject of fascination. When a celebrity sheds the kilos, it sparks curiosity: How did they do it? Their transformations are not just physical; they also reflect dedication, discipline and a strong sense of personal well-being. Let us take a look at seven Bollywood celebrities who stunned fans with drastic weight loss and shared the diet and lifestyle changes that helped them get there, earning them the spotlight they truly deserved. 7 Bollywood Celebrities Who Stunned Us With Drastic Weight Loss: 1. Karan Johar Says OMAD Helped Him Lose Weight Without Quick Fixes Recently, shutting down rumours about taking Ozempic for weight loss, filmmaker Karan Johar credited the OMAD diet (One Meal A Day) as the real reason behind his transformation in an interview with Raj Shamani. Combined with a cleaner, portion-controlled diet without glucose, gluten and lactose, Karan says this routine helped him feel lighter and more energetic. He also mentioned that staying consistent was key, rather than following extreme diets or quick fixes. 2. Bharti Singh Lost 16 Kilos Without The Gym Comedian Bharti Singh stunned fans by losing 16 kilos over 10 months-without hitting the gym. Her secret? She stopped eating after 7 PM and stuck to a simple time-restricted eating pattern. Bharti did not follow a strict diet but focused on eating home-cooked meals during the day. She also did not cut out her favourite foods, making her journey feel sustainable. The result was improved energy, confidence, and better health, all without drastic lifestyle changes. Read the full interview with NDTV Food. 3. Vidya Balan Switched To Anti-Inflammatory Foods Actress Vidya Balan is often candid about her health struggles. In an interview with Galatta India, she revealed that inflammation was the reason behind her weight gain and that switching to an anti-inflammatory diet helped her shed extra weight. Along with proper hydration and a focus on mindful eating, Vidya's transformation was gradual but noticeable. She believes in listening to her body and not falling for diet fads. Click here to learn more about her weight loss journey. 4. Ram Kapoor Dropped 55 Kilos With Intermittent Fasting TV and film actor Ram Kapoor underwent a major transformation, dropping 55 kilos in 18 months. He followed a rigorous intermittent fasting schedule and reportedly did not eat for 16 hours a day. He eliminated dairy, oil, most carbs and sugar from his diet. Ram emphasised that the journey was more mental than physical, requiring a shift in lifestyle and attitude more than anything else. Ram Kapoor revealed more details about his journey. Read here. 5. Adnan Sami Lost 150 Kilos Through Diet And Medical Support Singer Adnan Sami's transformation remains one of the most talked-about in the industry. He lost a staggering 150 kilos in just over a year. Adnan followed a strict low-calorie, low-carb and high-protein diet, completely cutting out sugar and oil. He also stopped eating after 6 PM. With the help of doctors and nutritionists, he made long-term changes to his food habits, proving that determination can truly change one's life. Learn more about his weight loss diet here. 6. Bhumi Pednekar Dropped 25 Kilos In Four Months Actress Bhumi Pednekar lost 25 kilos in just four months through sheer commitment. She did not rely on crash diets; instead, she focused on a balanced diet, cutting out sugar, junk food and refined carbs. Her meals were loaded with fruits, vegetables and lean proteins, and she started her day with aloe vera juice. She paired this with regular exercise, including weight training and cardio, highlighting that sustainable weight loss comes from consistency and lifestyle balance. Here is the full story. 7. Kapil Sharma Followed The 21-21-21 Rule For Healthier Habits Comedian Kapil Sharma lost an impressive 11 kilos by returning to basics, eating home-cooked food and staying away from fried items. He adopted the 21-21-21 rule to change his diet habits gradually and gave up liquor and coffee. Kapil's approach was holistic, blending mindful eating with regular activity. He also spoke about the importance of mental well-being and reduced stress playing a major role in his health journey. Click here to know more. Weight Loss Is About Consistency, Not Shortcuts These celebrity transformations remind us that there is no one-size-fits-all when it comes to weight loss. Whether it is intermittent fasting, clean eating or portion control, what works is consistency, balance and listening to your body. After all, the real "diet plan" is one that you can stick to for life, not just for the camera.
Daily Mail
3 hours ago
- Health
- Daily Mail
Ozempic found to slash risk of disease affecting 6.7m Americans each year
Blockbuster weight loss drugs could slash the risk of developing memory-robbing dementia, a major study suggests. Researchers in Ireland analyzed clinical trials of nearly 165,000 taking drugs to lower their glucose (blood sugar) and treat diabetes. The team found most glucose-lowering treatments had no significant impact on dementia risk. However, people taking GLP-1 agonists like Ozempic and Wegovy were 45 percent less likely to develop dementia at some point in their lives than people on other drugs. While it's unclear exactly how the active ingredients in these drugs - most often semaglutide and tirzepatide - reduce the likelihood of dementia, the researchers believe they may lower inflammation in the brain. Neuroinflammation is thought to damage neurons and disrupt communications to part of the brain responsible for memory, triggering dementia symptoms. GLP-1 agonists may also reduce toxic amyloid and tau proteins, hallmarks of dementia. The team suspects GLP-1 agonists like Ozempic may help prevent both diabetes and dementia, both of which are on the rise in the US. Dr Catriona Reddin, senior study author and researcher at the University of Galway, said: 'This research represents a significant contribution to our understanding of how some diabetes medications may impact brain health. 'Diabetes is a known risk factor for dementia, but whether glucose-lowering therapies can help prevent cognitive decline has remained unclear. 'Our findings suggest that GLP-1 receptor agonists, in particular, may have a protective effect on brain health.' The study comes after a similar experiment from the University of Florida, which tracked 400,000 Americans on glucose-lowering drugs and found dementia risk was 33 percent lower for GLP-1 users compared to other interventions. Around 8million adults in the US have some form of dementia, and 500,000 are diagnosed every year. Meanwhile, one in eight US adults has reported taking Ozempic or similar medications at least once for diabetes or weight loss. In the new study, published in JAMA Neurology, researchers identified 26 studies that explored the relationship between GLP-1 agonist use and dementia. These included a total of 164,531 participants, most of whom (65 percent) were men. The average age was 64 with a follow-up time of 31 months. Studies included in the analysis were published between 2015 and 2024. Of the 26 in the review, 10 looked at the impact of GLP-1 agonists. The team suspected GLP-1 agonists may lower inflammation, which is a major driver of dementia. It's thought to activate the immune cells microglia and astrocytes in the brain, which damage neurons and disrupt the blood-brain barrier, the brain's protective layer. GLP-1 agonists have also been shown to lower blood pressure and protect blood vessels, reducing the risk of vascular dementia. A study published in April also found GLP-1s may stimulate neural growth in the hippocampus, an area of the brain responsible for learning and memory formation. However, this research is early. Professor Martin O'Donnell, Dean of the College of Medicine, Nursing and Health Sciences at University of Galway: 'Given the increasing prevalence of both diabetes and dementia, findings from this study have important public health implications for prevention of dementia.' Recent reports from the Alzheimer's Association report rates of Alzheimer's disease - the most common form of dementia - have risen 25 years in a row in the US. Diabetes, meanwhile, affects 12 percent of Americans - 38million. Reports published in 2022 suggest rates in the Americas have tripled in the last 30 years. There were several limitations to the new study, mainly including a lack of data on subtypes of dementia like vascular and Lewy body dementia.
Leader Live
3 hours ago
- Health
- Leader Live
Weight loss jab Mounjaro linked to lower dementia risk
Academics said the benefits of drugs such as Wegovy and Mounjaro – including for managing weight and blood sugar levels – are well known, but other health benefits of the popular drugs remain 'unclear'. People with type 2 diabetes and obesity who are taking the drugs are also less likely to die prematurely, researchers found. The study saw experts from Taiwan examine date on 60,000 people from around the world, with an average age of 58, who had type 2 diabetes and obesity. Key differences between three weight-loss injections: Mounjaro, Wegovy, and Ozempic. Around half were given GLP agonist drugs semaglutide and tirzepatide – which are sold under the brand names Wegovy and Mounjaro. Semaglutide is also the main ingredient for the type 2 diabetes drug Ozempic. GLP agonists can reduce a person's appetite; slow down their digestion; reduce the amount of sugar the liver makes and they help the body to make more insulin when needed. The other half used other anti-diabetic medication. 📢Important update Eligible people in #Dorset will be able to access Tirzepatide (Mounjaro) weight management medication from autumn 2025. ✅Around 1,000 people in Dorset will qualify under strict national criteria ✅No need to contact your doctor More: During a seven-year follow-up period, researchers found that people given the GLP agonist drugs appeared to have a 37% lower risk of dementia and a 19% reduced risk of stroke. They were also 30% less likely to die during the follow-up period. And when researchers looked at the data further they found even greater benefits in people aged 60 or older, women, and those with a body mass index score of 30 to 40. They found no differences in Parkinson's disease or brain bleeds. The academics said their findings suggest 'potential neuroprotective and cerebrovascular benefits' of the drugs but they called for more studies to confirm the findings. Recommended reading: 'These findings suggest that semaglutide and tirzepatide may offer neuroprotective and cerebrovascular benefits beyond glycemic control, potentially improving long-term cognitive and survival outcomes in adults with type 2 diabetes and obesity,' they wrote in the journal JAMA Network Open. Commenting on the study, Professor Tara Spires-Jones, director of the Centre for Discovery Brain Sciences at the University of Edinburgh and group leader in the UK Dementia Research Institute, said: 'This is a very interesting study adding to evidence that GLP1 receptor agonists are associated with a lower risk of dementia in people with type 2 diabetes and obesity. 'This type of study cannot determine whether the drugs reduced disease risk by directly protecting the brain. 'It is highly likely that effectively treating type 2 diabetes and obesity would reduce dementia and stroke risk as they are known risk factors for these conditions. 'Further work is needed including randomised clinical trials to confirm these drugs are protective in people with diabetes and obesity and other trials are needed to determine whether these drugs will be protective in people who do not have type 2 diabetes and obesity.' Recommended reading: Dr Richard Oakley, associate director of research and innovation at Alzheimer's Society, said: 'It is well established that diabetes and obesity can increase your risk of developing dementia. 'This study supports existing evidence that shows these drugs may reduce dementia risk, particularly for people aged 60 and over who are living with type 2 diabetes and obesity. 'Although interesting, we can't draw conclusions from this study alone as it is an observational study, only a small number of people who took part went on to develop dementia and as the impact of these drugs on different types of dementia is not clear. 'There are clinical trials currently looking at whether drugs like these can be used to treat early-stage Alzheimer's disease, so this is a really exciting area being explored in the research fight against dementia.'
Glasgow Times
3 hours ago
- Health
- Glasgow Times
Weight loss jab Mounjaro linked to lower dementia risk
Academics said the benefits of drugs such as Wegovy and Mounjaro – including for managing weight and blood sugar levels – are well known, but other health benefits of the popular drugs remain 'unclear'. People with type 2 diabetes and obesity who are taking the drugs are also less likely to die prematurely, researchers found. The study saw experts from Taiwan examine date on 60,000 people from around the world, with an average age of 58, who had type 2 diabetes and obesity. Key differences between three weight-loss injections: Mounjaro, Wegovy, and Ozempic. — Paul Wischmeyer MD (@Paul_Wischmeyer) July 4, 2025 Around half were given GLP agonist drugs semaglutide and tirzepatide – which are sold under the brand names Wegovy and Mounjaro. Semaglutide is also the main ingredient for the type 2 diabetes drug Ozempic. GLP agonists can reduce a person's appetite; slow down their digestion; reduce the amount of sugar the liver makes and they help the body to make more insulin when needed. The other half used other anti-diabetic medication. 📢Important update Eligible people in #Dorset will be able to access Tirzepatide (Mounjaro) weight management medication from autumn 2025. ✅Around 1,000 people in Dorset will qualify under strict national criteria ✅No need to contact your doctor More: — NHS Dorset (@NHSDorset) June 23, 2025 During a seven-year follow-up period, researchers found that people given the GLP agonist drugs appeared to have a 37% lower risk of dementia and a 19% reduced risk of stroke. They were also 30% less likely to die during the follow-up period. And when researchers looked at the data further they found even greater benefits in people aged 60 or older, women, and those with a body mass index score of 30 to 40. They found no differences in Parkinson's disease or brain bleeds. The academics said their findings suggest 'potential neuroprotective and cerebrovascular benefits' of the drugs but they called for more studies to confirm the findings. Recommended reading: 'These findings suggest that semaglutide and tirzepatide may offer neuroprotective and cerebrovascular benefits beyond glycemic control, potentially improving long-term cognitive and survival outcomes in adults with type 2 diabetes and obesity,' they wrote in the journal JAMA Network Open. Commenting on the study, Professor Tara Spires-Jones, director of the Centre for Discovery Brain Sciences at the University of Edinburgh and group leader in the UK Dementia Research Institute, said: 'This is a very interesting study adding to evidence that GLP1 receptor agonists are associated with a lower risk of dementia in people with type 2 diabetes and obesity. 'This type of study cannot determine whether the drugs reduced disease risk by directly protecting the brain. 'It is highly likely that effectively treating type 2 diabetes and obesity would reduce dementia and stroke risk as they are known risk factors for these conditions. 'Further work is needed including randomised clinical trials to confirm these drugs are protective in people with diabetes and obesity and other trials are needed to determine whether these drugs will be protective in people who do not have type 2 diabetes and obesity.' Recommended reading: Dr Richard Oakley, associate director of research and innovation at Alzheimer's Society, said: 'It is well established that diabetes and obesity can increase your risk of developing dementia. 'This study supports existing evidence that shows these drugs may reduce dementia risk, particularly for people aged 60 and over who are living with type 2 diabetes and obesity. 'Although interesting, we can't draw conclusions from this study alone as it is an observational study, only a small number of people who took part went on to develop dementia and as the impact of these drugs on different types of dementia is not clear. 'There are clinical trials currently looking at whether drugs like these can be used to treat early-stage Alzheimer's disease, so this is a really exciting area being explored in the research fight against dementia.'
